Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

ROCKVILLE, Md., Nov. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for the three- and nine-month periods ending September 30, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Revenues for the third quarter 2008 were approximately $3,501,000 versus $3,520,000 for the comparable period a year ago. The Company reported a net loss for the third quarter of approximately ($3.4 million) or ($0.04) per share. This compares with a net loss of approximately ($3.0 million), or ($0.04) per share for the same period last year.

Revenues for the nine months ended September 30, 2008 were approximately $3,501,000 versus $3,520,000 for 2007. Reported net loss for the first nine months of 2008 was ($21.3 million), or ($0.26) per share as compared to ($18.6 million) or ($0.23) per share for 2007. As of September 30, 2008, EntreMed had cash and short-term investments of approximately $28 million.

Dane R. Saglio, EntreMed Chief Financial Officer, commented, "We have estimated that the royalty revenue from sales of Thalomid(R) for the 3rd quarter will be $3.5 million and we expect royalty revenue for the year to increase over 2007 with Celgene's acquisition of Pharmion Corporation. Research and development expenses for the third quarter declined versus the prior quarters in 2008 due in part to the decision made earlier in the year to discontinue the use of Panzem in oncology, but also impacted by a decreasing number of patients being treated with MKC-1 related to Phase 2 trials ini
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... March 31, 2015 Eastern Kentucky ... for online bachelor’s of criminal justice degree programs ... people to inspiring ideas and high quality educational ... to the University. We are confident that students ... , This is the site’s first “Students before ...
(Date:3/31/2015)... 31, 2015  Sonoa Health, a health tech startup ... developed a world-first consumer health portal, Health&, which brings ... devices and more. Today, the Company appointed ... CEO, who brings to the table more than 18-years ... included working closely with the biggest names in Silicon ...
(Date:3/31/2015)... CITY , March 31, 2015  The Myeloma ... with the selection of ten proposals that will ... is the first patient-led, scientifically validated funding initiative ... Stage 2 of the MCRI included preliminary ... review of a large number of innovative projects ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 This June ... from the top U.S and International Medical Schools will ... latest research on the application of stem cell therapy ... symposium is organized and funded by the Ocular ... that has been convening intimate meetings of top experts ...
Breaking Biology Technology:EKU Ranked in Top 50 Among Online Criminal Justice Degrees 2Investment Banker Appointed CEO of Australian Health Tech Start-Up 2Investment Banker Appointed CEO of Australian Health Tech Start-Up 3Myeloma Crowd Research Initiative Selects 10 High-Risk Multiple Myeloma Proposals For Further Review 2Sight Restoration Through Stem Cell Therapy - Subject of June Symposium of Experts 2
... Oct. 21 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. ("SemBioSys") ... entered into a definitive agreement to acquire all ... Specialty Ingredients Inc. ("Botaneco") held by SemBioSys and ... an initial 9.48 percent shareholding in Advitech, in ...
... BEIJING, Oct. 20, 2009 Monsanto Company and Huazhong ... the development of novel traits such as higher yield, ... and advance certain technologies developed by Professor Qifa Zhang,s ... "We,re excited to be working with a prominent research ...
... 20 NuVasive, Inc. (Nasdaq: NUVA ... minimally disruptive surgical treatments for the spine, announced today financial ... reported third quarter revenue of $94.9 million, a 41.8% increase ... a 7.3% increase over the $88.5 million for the second ...
Cached Biology Technology:SemBioSys provides an update on Botaneco 2SemBioSys provides an update on Botaneco 3SemBioSys provides an update on Botaneco 4Monsanto and Huazhong Agricultural University Enter Into Collaboration Focusing on Development of Plant Biotechnology 2Monsanto and Huazhong Agricultural University Enter Into Collaboration Focusing on Development of Plant Biotechnology 3NuVasive Reports Third Quarter 2009 Financial Results 2NuVasive Reports Third Quarter 2009 Financial Results 3NuVasive Reports Third Quarter 2009 Financial Results 4NuVasive Reports Third Quarter 2009 Financial Results 5NuVasive Reports Third Quarter 2009 Financial Results 6NuVasive Reports Third Quarter 2009 Financial Results 7NuVasive Reports Third Quarter 2009 Financial Results 8NuVasive Reports Third Quarter 2009 Financial Results 9NuVasive Reports Third Quarter 2009 Financial Results 10NuVasive Reports Third Quarter 2009 Financial Results 11NuVasive Reports Third Quarter 2009 Financial Results 12
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... is one of the products featured in 2015 "I ... at 11:00 PM EST on the DIY Network.   ... Las Vegas , site of the 2015 ...
(Date:3/17/2015)... 17, 2015 MedNet Solutions , ... clinical study management systems, is pleased to announce ... ARENA,s Outsourcing in Clinical Trials Southeast conference – ... an excellent forum for MedNet to showcase ... software-as-a-service (SaaS) eClinical technology platform. We ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... YORK (August 21, 2013) Reproductive genetics researchers ... a multicenter prospective clinical study investigating the effects ... prenatally through microarray analysis. The goal of the ... variances previously not well reported in the medical ...
... July issue of the Journal of Spinal Cord Medicine ... Cord Injury." Guest Editor Rory Cooper, PhD, is a member ... FISA/PVA Endowed Chair and a Distinguished Professor of the Department ... Sciences, University of Pittsburgh. He is also the Center ...
... Amsterdam, NL, 21 August 2013 Metals such as ... processes. In recent years, studies have shown that these ... brains and some animal models of AD. Scientists are ... seen in AD or are indicative of other ongoing ...
Cached Biology News:Trial aims to advance prenatal diagnosis of genetic defects 2Trial aims to advance prenatal diagnosis of genetic defects 3Trial aims to advance prenatal diagnosis of genetic defects 4Journal of Spinal Cord Medicine publishes special issue on assistive technology 2Elevated levels of copper in amyloid plaques associated with neurodegeneration in mouse models of AD 2
... Use in any standard fixed-angle microcentrifuge ... g.,Spin- centrifuge tube filters consist ... a centrifuge tube. They filter by ... HPLC sample preparation, removal of cells ...
... reduce the chance of error. Thats the ... using Beckman Coulters extensive experience in laboratory ... the CEQ 8000 is a fully automated ... the capillary array with a patented linear ...
... The CHEMICON MDR1 Shift Assay provides a ... that occur upon transport of MDR1 substrates. Thus, ... extent to which small molecules act as transport ... increased in the presence of MDR1 substrates, the ...
... SDS Kit is a simple high performance ... Removes detergents without significant dilution of ... solution on the Detergent-OUT Spin column and ... columns are suitable for removing detergent from ...
Biology Products: